Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
复制标题
DOI：
10.1016/j.ejim.2020.05.011
复制
发表时间：
2020-06-01
影响因子：
8
通讯作者：
Corbellino, Mario
中科院分区：
文献类型：
--
作者：
Morena, Valentina;Milazzo, Laura;Corbellino, Mario
背景：Tocilizumab是一种人源化单克隆抗体，靶向IL-6受体，阻断IL-6的下游促炎作用。在初步报告中，建议对严重COVID-19患者有益。方法：在这项开放标签前瞻性研究中，我们描述了51例确诊和严重COVID-19肺炎住院患者接受托珠单抗静脉治疗的临床特征和结局。所有患者的血浆IL-6水平均升高（>40 pg/mL），
Background: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream proinflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19.Methods: In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. All patients had elevated IL-6 plasma level (>40 pg/mL) and oxygen saturation